Research Briefing in 2022

Filter By:

Article Type
Year
  • Mesenchymal-like and pluripotency-like programs coordinate the dissemination and long-lived dormancy of early breast cancer cells. The transcription factor ZFP281 controls these programs, preventing the acquisition of an epithelial-like proliferative phenotype and serving as a previously unrecognized barrier to metastasis.

    Research Briefing
  • Immunotherapy has shown great promise in the treatment of patients with advanced non-small-cell lung cancer. We show that integration of data collected during diagnostic clinical work-up with machine learning has the potential to improve predictions of response to immunotherapy and to identify the patients most likely to benefit.

    Research Briefing
  • Many patients with colorectal cancer (CRC) relapse after chemotherapy. Tumor cells that do not completely adapt to their environment (owing to an incomplete set of CRC driver mutations) enter a latent state, in which the expression of Mex3a is upregulated. Mex3a+ cells are chemoresistant and reactivate after treatment, which leads to regeneration of the disease.

    Research Briefing
  • The transcription factor IKAROS is essential to maintaining a leukemogenic gene-expression profile mediated by transcription factors encoded by HOXA@ and MEIS1 in MLL1-rearranged (MLL-r) acute myeloid leukemia. Pharmacological degradation of IKAROS increases the effectiveness of inhibitors of the MLL1–MENIN protein–protein interaction, which leads to more-robust disruption of leukemogenic transcriptional networks and enhanced therapeutic benefit in preclinical models.

    Research Briefing
  • People with lymphoma have immune defects that compromise the immune response to vaccination. A prospective observational study of 457 people with lymphoma showed improvement in antibody and T cell responses after the third vaccine dose except in those who received anti-CD20 antibody therapy within a year prior to vaccination.

    Research Briefing
  • Mitochondrial fission in macrophages is essential for the phagocytosis of tumor cells. Resistance of tumor cells to phagocytosis involves overexpression of GFPT2, an enzyme involved in glutamine metabolism; this results in lower nutrient availability for macrophages to support mitochondrial fission and prevents assembly of the phagocytic machinery.

    Research Briefing